Exploratory data found 34.8 months’ median survival in 39 patients with a low blood-cell ratio.

AIM ImmunoTech highlighted exploratory data showing 34.8 months' median survival in 39 pancreatic cancer patients with low neutrophil-to-lymphocyte ratio. Final dosing is complete in the DURIPANC trial with AstraZeneca's Imfinzi, but endpoint reporting is pending. The company is pursuing further clinical development and partnerships for a Phase 3 study.

Original reporting
Published Oct 7, 2026, 1:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 1:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$AIM
Neutral
high confidence
Mentioned
$AIM
Relevance
8/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$AIMNeutralMed
01

Why it matters

The announcement provides the first public glimpse of potential efficacy for Ampligen in pancreatic cancer, which could influence analyst expectations and short‑term trading sentiment, though the lack of controlled data tempers impact.

02

Market read

First‑time disclosure of exploratory survival data may generate modest buying interest, but uncertainty around trial endpoints limits decisive action.

03

What to watch

Pending DURIPANC trial results and the need for a pivotal Phase 3 could delay any material upside.

Relevance 8/10Novelty 8/10Timing: today

Background

AIM ImmunoTech released a press statement highlighting exploratory survival data from a Dutch Named Patient Program and noting that the DURIPANC trial dosing is complete but endpoints are still pending.

Company-level read

Ticker impact

$AIMNeutralHigh confidence
Context

AIM ImmunoTech disclosed an exploratory analysis of 39 patients showing a median overall survival of 34.8 months in a named patient program for pancreatic cancer; primary and secondary endpoints of the DURIPANC trial are still pending.

Expected impact

modest upside as investors price in possible Phase 3 advancement, tempered by pending endpoint data

Evidence & confidence

Positive survival signal in a small, uncontrolled cohort may attract interest, but lack of controlled data limits immediate price move.

Market effects

May boost interest in immuno‑oncology and TLR3 agonist platforms across biotech sector.

Limited to US biotech investors; no broader regional effect.

Low global impact beyond niche oncology investors.

Counterpoint

The survival data comes from an uncontrolled program; investors may view it as insufficient to justify price gains.

Key entities

  • AIM ImmunoTech Inc.

    US‑listed biotech developing Ampligen for pancreatic cancer.

Related articles

$AIMLow

AIM ImmunoTech completes dosing in pancreatic cancer trial

AIM ImmunoTech (AIM) completed dosing in its Phase 2 DURIPANC trial for pancreatic cancer, with results expected in 2027. The trial tests Ampligen with AstraZeneca's Imfinzi. AIM reported Q3 2026 cash of $6.9M, R&D expenses of $846K, and a net loss of $3.1M. The company secured patents for Ampligen combinations and repaid a promissory note.